NCT06568172 2026-03-18
Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer
National Cancer Institute (NCI)
Phase 3 Recruiting
National Cancer Institute (NCI)
Ohio State University Comprehensive Cancer Center
Philogen S.p.A.
Vastra Gotaland Region
The Christie NHS Foundation Trust